Investors Overview

Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by bi-coastal centers of discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future.

Stock Quote

Exelixis, Inc

Volume:

Data as
Copyright West LLC.
Minimum 15 minutes delay.